# Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

> **NCT05049538** · — · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1000 (estimated)

## Conditions studied

- Endometrial Clear Cell Adenocarcinoma
- Endometrial Dedifferentiated Carcinoma
- Endometrial Mucinous Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Malignant Uterine Neoplasm
- Uterine Corpus Carcinosarcoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Liquid Biopsy
- **OTHER:** Pap Smear

## Key facts

- **NCT ID:** NCT05049538
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-18
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049538, "Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05049538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*